Clinical trial NCT01440192: Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
Official title: A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Stage 2 Pulmonary Sarcoidosis
Stage 3 Pulmonary Sarcoidosis
Keywords: Sarcoidosis
Stem cells
PDA001
Celgene
Human Placenta-Derived cells
Cenplacel-L
Lead sponsor: Celularity Incorporated
Sponsor class: INDUSTRY
First posted: 2011-09-26
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to assess the safety and tolerability of a single dose of PDA001 (given twice) in subjects with Stage II or III Pulmonary Sarcoidosis (PS) who are refractory to one or more of the following treatments for PS: methotrexate,immunosuppressants or cytotoxic agents.


Eligibility criteria: Inclusion Criteria:

1. Male or female subjects 18 years to 75 years of age at the time of signing the informed consent document
2. Understand and voluntarily sign an informed consent document prior to any study-related assessments/procedures are conducted
3. Must be able to adhere to the study visit schedule and other protocol requirements
4. Weight must be ≥ 50 kg
5. A female of childbearing potential (FCBP) must have a negative serum or urine pregnancy test within 24 hours prior to treatment with study therapy. In addition, sexually active FCBP must agree to use two of the following adequate forms of contraception methods simultaneously such as: oral, injectable or implantable hormonal contraception; tubal ligation; intrauterine device; barrier contraceptive with spermicide; or vasectomized partner for the duration of the study and the follow-up period. Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP for the duration of the study and the follow-up period
6. Diagnosis of sarcoidosis as evidenced by parenchymal disease on chest radiograph (Stage II or III), as well as histologic confirmation of granulomatous inflammation and disease duration of ≥ 1 year
7. Refractory to one or more of the following; methotrexate, immunosuppressants or cytotoxic agents
8. Forced vital capacity (FVC) of ≥ 45% and ≤ 80% of predicted normal value at screening
9. Must be on a stable dose of prednisone, methotrexate, and/or azathioprine for pulmonary Sarcoidosis for 4 weeks prior to infusion of the IP

Exclusion Criteria:

1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
2. Any condition that confounds the ability to interpret data from the study
3. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
4. Subjects with Stage I or Stage IV sarcoidosis
5. Subjects with cutaneous sarcoidosis only
6. Subjects with neurosarcoidosis or (clinically apparent) cardiac sarcoidosis
7. Lung disease, other than sarcoid related, such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD)
8. History of listeriosis, coccidiomycosis, histoplasmosis, blastomycosis, treated or untreated tuberculosis or exposure to individuals with tuberculosis
9. History of pulmonary emboli or deep vein thrombus
10. Active smoker or previous smoker \> 10 pack years (PY). Previous smokers must have discontinued smoking for at least 1 year
11. Morbidly obese \[Body Mass Index (BMI)\] \> 35 at screening)
12. Inability to perform 6 Minute Walk Test (6MWT) or Pulmonary Function Test (PFT) maneuvers
13. Sickle cell disease (Hemoglobin SS, Hemoglobin SC, and sickle cell-beta thalassemia)
14. Treatment at any time with B cell depleting therapies
15. Any biologic anti-tumor necrosis factor (anti-TNF) therapy within the previous year
16. Active infection requiring treatment within 30 days prior to screening
17. Pregnant or lactating females
18. Aspartate transaminase (AST), alanine aminotransferase (ALT) or creatine phosphokinase (CPK) \> 2 x the upper limit of normal at screening
19. Active infection with hepatitis B or hepatitis C
20. Known infection with human immunodeficiency virus (HIV)
21. Creatinine level \> 1.5 times the upper limit of normal
22. Platelet count \< 100,000/µL (\< 100 x 109/L)
23. White blood cell count \< 3,000/cu mm (\< 3.0 x 109/L) or \>20,000/cu mm (\> 20 x 109/L)
24. Organic heart disease (e.g., congestive heart failure, cor pulmonale), myocardial infarction within six months prior to screening
25. Clinically significant findings on electrocardiogram (ECG) at screening (eg, arrhythmia)
26. History of other malignancies within 5 years (except basal cell carcinoma of the skin that is surgically cured, remote history of cancer now considered cured or positive Pap smear with subsequent negative follow-up)
27. Documented prior history of neurological disease or evidence of ongoing neurological disease
28. Known allergy to bovine or porcine products
29. Subject has received an investigational agent (an agent or device not approved by Federal Drug Administration (FDA) for marketed use in any indication) within 90 days (or 5 half-lives, whichever is longer) prior to treatment with investigational product (IP)
30. Subject who has received previous cell therapy
31. Subject is expecting to have elective surgery within 12 weeks prior to or post dosing with IP if the surgery would be expected to confound evaluation of outcome endpoints

Primary outcomes:
measure: Evaluate pulmonary artery pressure during infusion
timeFrame: Day 1
measure: Adverse Events
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
measure: Evaluate pulse oximetry during infusion
timeFrame: Day 1 and Day 8
Secondary outcomes:
measure: Change from baseline thru study day 731 in forced vital capacity (FVC)
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
measure: Change from baseline thru study day 731 in forced expiratory volume (FEV1)
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
measure: Change from baseline thru study day 731 in diffusing capacity of the lung for carbon monoxide (DLCO)
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
measure: Change from baseline thru study day 731 in 6 minute walk test (6MWT)
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
measure: Change from baseline thru study day 731 in St. George's Respiratory Questionnaire (SGRQ).
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
measure: Change from baseline thru study day 731 in Fatigue Assessment Score (FAS)
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
measure: Change from baseline thru study day 731 in baseline dyspnea index (BDI)/ transitional dyspnea index (TBI
timeFrame: 24 months ( 2 years) from first dose - Study Day 1
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama, Birmingham - Division of Pulmonary, Allergy, and Critical Care Medicine
state: Alabama
city: Denver
country: United States
facility: National Jewish Health
state: Colorado
city: Cincinnati
country: United States
facility: University of Cincinatti Medical Center
state: Ohio
city: Cleveland
country: United States
facility: The Cleveland Clinic Foundation - Respiratory Institute
state: Ohio
Study officials:
affiliation: Celularity Incorporated
name: Monica E Luchi, MD
role: STUDY_DIRECTOR
References: